Oxford Researchers Develop Vaccine for Cancer-Linked Genetic Disorder

LynchVax project aims to prevent cancers in Lynch syndrome patients by targeting pre-cancerous cells

Oxford scientists are developing a vaccine for Lynch syndrome, a genetic condition linked to increased cancer risk.
Lynch syndrome affects about one in 400 people in England, significantly raising the risk of bowel, womb, and ovarian cancers.
The LynchVax project aims to teach the immune system to destroy pre-cancerous cells in individuals with Lynch syndrome.
Current research is in early stages, but hopes are high for preventing multiple cancer types associated with the condition.
Cancer Research UK has awarded £550,000 to the LynchVax team to support the development of this potential vaccine.